RT Journal Article
SR Electronic
T1 Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group
JF RMD Open
JO RMD Open
FD EULAR
SP e003022
DO 10.1136/rmdopen-2023-003022
VO 9
IS 2
A1 Francesco Ursini
A1 Piero Ruscitti
A1 Olga Addimanda
A1 Rosario Foti
A1 Vincenzo Raimondo
A1 Giuseppe Murdaca
A1 Virginia Caira
A1 Erika Pigatto
A1 Giovanna Cuomo
A1 Alberto Lo Gullo
A1 Ilaria Cavazzana
A1 Corrado Campochiaro
A1 Caterina Naclerio
A1 Rossella De Angelis
A1 Jacopo Ciaffi
A1 Luana Mancarella
A1 Veronica Brusi
A1 Elena Marchetti
A1 Francesca Motta
A1 Marcella Visentini
A1 Sebastiano Lorusso
A1 Maria De Santis
A1 Giacomo De Luca
A1 Laura Massaro
A1 Domenico Olivo
A1 Roberta Pellegrini
A1 Francesca Francioso
A1 Jessica Luppino
A1 Ilenia Di Cola
A1 Roberta Foti
A1 Giuseppe Varcasia
A1 Francesco Caso
A1 Massimo Reta
A1 Lorenzo Dagna
A1 Carlo Selmi
A1 Annamaria Iagnocco
A1 Roberto Giacomelli
A1 Florenzo Iannone
A1 Clodoveo Ferri
YR 2023
UL http://rmdopen.bmj.com/content/9/2/e003022.abstract
AB Objectives To better define the spectrum of new-onset post-COVID-19 and post-COVID-19 vaccine inflammatory rheumatic diseases (IRD) from a large multicentric observational study.Methods Consecutive cases of IRD encountered during a 12-month period and satisfying one of the following inclusion criteria: (a) onset of the rheumatic manifestations within 4 weeks from SARS-CoV-2 infection or (b) onset of the rheumatic manifestations within 4 weeks from the administration of one of the COVID-19 vaccines ws recruited.Results The final analysis cohort comprised 267 patients, of which 122 (45.2%) in the post-COVID-19 and 145 (54.8%) in the postvaccine cohort. Distribution of IRD categories differed between the two cohorts: the post-COVID-19 cohort had a higher percentage of patients classified as having inflammatory joint diseases (IJD, 52.5% vs 37.2%, p=0.013) while the post-vaccine cohort had a higher prevalence of patients classified as polymyalgia rheumatica (PMR, 33.1% vs 21.3%, p=0.032). No differences were detected in the percentage of patients diagnosed with connective tissue diseases (CTD 19.7% vs 20.7%, p=0.837) or vasculitis (6.6% vs 9.0%, p=0.467). Despite the short follow-up period, IJD and PMR patients’ response to first-line therapy was favourable, with both groups achieving a drop in baseline disease activity scores of ~30% and ~70% respectively.Conclusion Our article reports the largest cohort published to date of new-onset IRD following SARS-CoV-2 infection or COVID-19 vaccines. Although causality cannot be ascertained, the spectrum of possible clinical manifestations is broad and includes IJD, PMR, CTD and vasculitis.Data are available upon reasonable request.